Literature DB >> 12492623

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.

Marek Malik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12492623      PMCID： PMC1874496          DOI： 10.1046/j.0306-5251.2002.01661.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Problems of heart rate correction in assessment of drug-induced QT interval prolongation.

Authors:  M Malik
Journal:  J Cardiovasc Electrophysiol       Date:  2001-04

2.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval.

Authors:  M Malik; P Färbom; V Batchvarov; K Hnatkova; A J Camm
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

Review 3.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability.

Authors:  Velislav N Batchvarov; Azad Ghuran; Peter Smetana; Katerina Hnatkova; Monica Harries; Polychronis Dilaveris; A John Camm; Marek Malik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06       Impact factor: 4.733

5.  Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.

Authors:  M S Gillen; B Miller; P Chaikin; J Morganroth
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335
  5 in total
  3 in total

1.  Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.

Authors:  P Chaikin; M S Gillen; M Malik; H Pentikis; G R Rhodes; D J Roberts
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

2.  A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults.

Authors:  Rosa M Antonijoan; Consuelo García-Gea; Montserrat Puntes; Marta Valle; Ramon Esbri; Josep Fortea; Manuel J Barbanoj
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.

Authors:  Robert J Noveck; Richard A Preston; Suzanne K Swan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.